Related Experiment Videos
Endobronchial non-Hodgkin's lymphoma
1Department of Thoracic Surgery, Bradford Royal Infirmary, England.
The Journal of Cardiovascular Surgery
|August 1, 1993
Summary
Endobronchial non-Hodgkin's lymphoma is rare but can cause airway obstruction. Self-expanding endobronchial stents offer relief for patients with rapid dyspnea, alongside chemotherapy or radiotherapy.
Area of Science:
- Oncology
- Pulmonology
- Hematology
Background:
- Endobronchial involvement in non-Hodgkin's lymphoma (NHL) is an uncommon manifestation, even in advanced stages.
- This review examines two novel cases and synthesizes data from 31 previously reported instances of endobronchial NHL.
Observation:
- The reviewed cases comprised 16 with diffuse endobronchial involvement alongside systemic NHL, and 15 with central airway involvement without apparent systemic disease.
- Symptoms included dyspnea due to airway obstruction, particularly in cases of primary endobronchial NHL.
Findings:
- Chemotherapy, potentially combined with radiotherapy, is the standard treatment for disseminated disease and primary endobronchial NHL.
- Surgical resection may be considered for primary endobronchial NHL if feasible, with adjuvant therapy for residual disease.
- Older patients are candidates for curative-intent chemotherapy unless comorbidities interfere.
Implications:
- Prompt intervention with self-expanding endobronchial stents can effectively alleviate acute airway obstruction and dyspnea in NHL patients.
- This highlights a palliative option for symptom management in advanced or primary endobronchial lymphoma.
- Optimal treatment strategies balance curative-intent therapies with palliative measures for symptom relief.